Replies to post #122511 on Biotech Values

[jb_118]

I’m waiting for someone to try to explain the factoid (mentioned in #msg-64637084) that drugs developed in-house by Big Pharma are 20% more likely to obtain regulatory approval than those that are in-licensed.

Probably depends on the definitions, specifically at what point do they start including "drugs that originate inside Big Pharma companies" in the denominator for big-pharma approval rates? Clearly they can't be including the myriad of pre-clinical compounds originating in big-pharma that never make phase I.

[ciotera]

drugs developed in-house by Big Pharma are 20% more likely to obtain regulatory approval

I don't know how the 20% was computed, but if the sample of drugs considered included brand extensions and "related" molecules then it wouldn't really be surprising - it's much easier to get approval for a modified version of an already approved product vs. in-licensed candidates are almost always truly innovative and as such more risky.